Your browser doesn't support javascript.
loading
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.
Song, Gina; Tarrant, Teresa K; White, Taylor F; Barrow, David A; Santos, Charlene M; Timoshchenko, Roman G; Hanna, Suzan K; Ramanathan, Ramesh K; Lee, Craig R; Bae-Jump, Victoria L; Gehrig, Paola A; Zamboni, William C.
Afiliação
  • Song G; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Tarrant TK; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • White TF; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Barrow DA; Cytokine and Biomarker Analysis Facility, Center for Oral and Systemic Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Santos CM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; The Animal Studies Core, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Timoshchenko RG; Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Hanna SK; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Ramanathan RK; Virginia G. Piper Cancer Institute, Scottsdale, AZ, USA.
  • Lee CR; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Center for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Bae-Jump VL; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Obstetrics and Gynecology, Division of Gynecology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Gehrig PA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Obstetrics and Gynecology, Division of Gynecology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Zamboni WC; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Carolina Center of Cancer Nanotech
Nanomedicine ; 11(7): 1797-807, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26093057

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Doxorrubicina / Neoplasias Epiteliais e Glandulares / Quimiocina CCL5 / Quimiocina CCL2 / Recidiva Local de Neoplasia Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Nanomedicine Assunto da revista: BIOTECNOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Doxorrubicina / Neoplasias Epiteliais e Glandulares / Quimiocina CCL5 / Quimiocina CCL2 / Recidiva Local de Neoplasia Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Nanomedicine Assunto da revista: BIOTECNOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos